Soligenix’s Promising Phase 2 Study on SGX302 for Psoriasis: A Potential Game-Changer

Soligenix Inc ((SNGX)) announced an update on their ongoing clinical study.

Soligenix Inc. is currently conducting a Phase 2 clinical study titled ‘Phase 2 Study Evaluating SGX302 (Synthetic Hypericin) in the Treatment of Mild-to-Moderate Psoriasis.’ The study aims to evaluate the effectiveness of SGX302, a topical hypericin ointment and gel, in improving lesions in patients with mild-to-moderate psoriasis over an 18-week treatment course. This study is significant as it explores a potential new treatment option for psoriasis, a common skin condition.

The intervention being tested is SGX302, which is a synthetic hypericin formulated as a 0.25% ointment or gel. It is applied to lesions and activated with visible light, aiming to reduce psoriasis symptoms.

The study design includes a randomized, sequential intervention model with two parts. Part A involves an open-label trial with 10-15 patients to assess tolerability and response. Part B will randomize approximately 32 patients into double-blind treatment groups, with a 1:1 ratio of active drug to placebo. The study employs quadruple masking to ensure unbiased results.

The study began on June 28, 2022, with a primary completion date yet to be announced. The latest update was submitted on June 4, 2025. These dates are crucial for tracking the study’s progress and potential market entry.

The outcome of this study could significantly impact Soligenix’s stock performance and investor sentiment, especially if SGX302 proves effective. It could position Soligenix as a competitive player in the psoriasis treatment market, potentially influencing the broader industry landscape.

The study is ongoing, with further details available on the ClinicalTrials portal.